|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 2, April-June 2020
IMMUNOTHERAPY FOR NON-SMALL CELL LUNG CANCER
RAMÓN ALBERT ANTONIO
Lung cancer (LC) is one of the most common malignancies, and non-small cell lung cancer (NSCLC) represents almost 85% of diagnosed cases of LC. For pa- tients with resectable early-stage NSCLC, surgery is the best therapeutic option when possible, and adjuvant chemotherapy provides an additional benefit.
At present, treatment options for patients with advanced disease include: chemotherapy, targeted
therapies, and immunotherapy; In specific cases, local treatment with radiotherapy or surgery is
recommended to palliate the symptoms. To stipulate the treatment, it is essential to know besides
the histological charac- teristics, the molecular and immunological characteristics of the tumor,
evaluat- ing the genomic changes of the tumor and the PD-L1 expression. Immunotherapy alone and
combined with chemotherapy has achieved superior benefits than for- mer standard treatments.
In this non-systematic review, the outcomes of the latest trials regarding the use of immunotherapy
in different conntttexts are discussed. Parallely, finding pre- dictive response biomarkers
anndd/oorr ccrriiteria for aan early response assessment is challenging.
ANTI-PD-1 – ANTI-PD-L1 – IMMUNE CHECKPOINT INHIBITORS – IMMUNOTHERAPY – NSCLC